Wiseman Susan and BRZE: what the latest Form 4 cycle says about ownership trend
Wiseman Susan's BRZE insider record stands at $13.5M cumulative sales (latest filing 2026-01-30); focus on sequence, transaction-code mix, and ownership trend over time.
Wiseman Susan (executive) remains an active monitor name for BRZE. The profile currently shows $13.5M cumulative sales with a latest filing timestamp of 2026-01-30.
Tape First
| Date | Code | Shares | Price | Est. Value |
|---|---|---|---|---|
| 2026-01-30 | J | 37,000 | $35.01 | $1.3M |
| 2026-01-30 | J | 37,000 | $35.01 | $1.3M |
| 2026-01-30 | J | 11,000 | $35.01 | $385K |
| 2026-01-30 | J | 11,000 | $35.01 | $385K |
| 2026-01-30 | J | 26,425 | $4.88 | $129K |
| 2026-01-30 | J | 26,425 | $4.88 | $129K |
| 2025-11-20 | S | 1,208 | $28.17 | $34K |
| 2025-11-20 | S | 3,248 | $27.35 | $89K |
Interpretation
A clean read should separate compensation-linked mechanics from discretionary selling behavior. Repeat timing is often the deciding variable.
Open-Web Layer
Search engine context for this insider case
Next Checks
- Next filing interval
- Code-mix shift
- Ownership change vs 37,000
Related Research
Explore all researchPrincipal’s Q4 2025 filing looked slightly weaker on headline AUM, but the internal rotation was more revealing: Brookfield became a top-ten position, Netflix surged, and the fund cut back in parts of real estate. The next filing will show whether that shift keeps going.
Apr 17, 2026
Nuveen’s Q4 2025 filing stayed large-cap and AI-heavy at the top, but the more revealing addition was a sizable fixed-income sleeve through NXUS and NHYB. The next filing will show whether those credit and bond ETFs remain central or fade back out.
Apr 17, 2026
Fisher’s Q4 2025 filing was still packed with mega-cap tech, but the bigger tell was a giant Treasury and investment-grade corporate bond sleeve built through IEF and VCIT. The next filing will show whether that duration bet was tactical or structural.
Apr 17, 2026
Dodge & Cox’s Q4 2025 filing barely moved on headline AUM, but the underlying changes were more interesting: fresh positions in Brookfield, TransUnion and PDD inside a still-diversified value book. The next filing will show whether those adds were conviction moves or just incremental reshuffling.
Apr 17, 2026
AQR’s Q4 2025 filing kept expanding, with AUM rising to $190.63B, 69 new names, and a dramatic Bristol Myers build inside an already broad book. The next filing will show whether the quant giant keeps pressing this expansion or starts normalizing the roster again.
Apr 17, 2026